Exact Mass: 405.15542080000006
Exact Mass Matches: 405.15542080000006
Found 500 metabolites which its exact mass value is equals to given mass value 405.15542080000006
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Clomifene
C26H28ClNO (405.18593080000005)
Clomifene is only found in individuals that have used or taken this drug. It is a triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. [PubChem]Clomifene has both estrogenic and anti-estrogenic properties, but its precise mechanism of action has not been determined. Clomifene appears to stumulate the release of gonadotropins, follicle-stimulating hormone (FSH), and leuteinizing hormone (LH), which leads to the development and maturation of ovarian follicle, ovulation, and subsequent development and function of the coprus luteum, thus resulting in pregnancy. Gonadotropin release may result from direct stimulation of the hypothalamic-pituitary axis or from a decreased inhibitory influence of estrogens on the hypothalamic-pituitary axis by competing with the endogenous estrogens of the uterus, pituitary, or hypothalamus. Clomifene has no apparent progestational, androgenic, or antrandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function. G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03G - Gonadotropins and other ovulation stimulants > G03GB - Ovulation stimulants, synthetic D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen D012102 - Reproductive Control Agents > D005299 - Fertility Agents C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
Roseoflavin
A benzopteridine that is riboflavin in which the methyl group at position 8 is substituted by a dimethylamino group.
Toremifene
C26H28ClNO (405.18593080000005)
Toremifene is only found in individuals that have used or taken this drug. It is a first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors. L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BA - Anti-estrogens D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
6-Acetonyl-5,6-dihydrochelerythrine
C24H23NO5 (405.15761480000003)
Nebivolol
Nebivolol is only found in individuals that have used or taken this drug. It is a highly cardioselective vasodilatory beta1 receptor blocker used in treatment of hypertension. In most countries, this medication is available only by prescription. [Wikipedia]Nebivolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4-Hydroxyphenylacetonitrile triacetylrhamnoside
4-Hydroxyphenylacetonitrile triacetylrhamnoside is a fully acetylated nitrile glycoside. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. 4-Hydroxyphenylacetonitrile triacetylrhamnoside is found in brassicas. Constituent of the leaves of the horseradish tree (Moringa oleifera, Moringaceae). 4-Hydroxyphenylacetonitrile triacetylrhamnoside is found in brassicas.
N-desalkyludenafil
C18H23N5O4S (405.14706780000006)
N-desalkyludenafil is a metabolite of udenafil. Udenafil is a drug used in urology to treat erectile dysfunction. It belongs to a class of drugs called PDE5 inhibitor, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. It was developed by Dong-A Pharmaceutical Co. , Ltd. and is marketed under the trade name ZydenaTM . It is not approved for use in the United States by the U.S. Food and Drug Administration. (Wikipedia)
2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
C26H28ClNO (405.18593080000005)
Nitro-prednisolone
C21H27NO7 (405.17874320000004)
Taltirelin
Hydroxy-roquefortine C
C22H23N5O3 (405.18008080000004)
CONFIDENCE Penicillium bissettii
(3E,5aS,10bR)-6,10b,11,11a-tetrahydro-11a-hydroxy-3-(1H-imidazol-5-ylmethylidene)-10b-(2-methylbut-3-en-2-yl)-2H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione|16-hydroxyroquefortine C
C22H23N5O3 (405.18008080000004)
12,13-Dihydro-1,2-dimethoxy-6-acetonyl-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridine
C24H23NO5 (405.15761480000003)
O-beta-D-galactopyranosyl-(1-->3)-O-beta-D-arabinofuranosyl-(1-->1)-cytosine
(E)-4-hydroxy-2-(hydroxymethyl)but-2-enenitrile 4-O-beta-D-glucopyranoside 6?-O-(2?S,3?R)-2?-ethyl-2?,3?-dihydroxybutyrate|microtropin D
C17H27NO10 (405.16348819999996)
5-acetoxymethyl-5,7,8,13,13b,14-hexahydro-indolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridine-1-carboxylic acid methyl ester|Cadamin-D-Acetat
C23H23N3O4 (405.16884780000004)
Ser Ala Asn Asp
Atropine sulfate monohydrate
Toremifene
C26H28ClNO (405.18593080000005)
L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BA - Anti-estrogens D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ala Ala Met Asn
Ala Ala Asn Met
Ala Cys Gly Arg
Ala Cys Asn Val
Ala Cys Arg Gly
Ala Cys Val Asn
Ala Asp Asn Ser
Ala Asp Ser Asn
Ala Gly Cys Arg
Ala Gly Met Gln
Ala Gly Gln Met
Ala Gly Arg Cys
Ala Met Ala Asn
Ala Met Gly Gln
Ala Met Asn Ala
Ala Met Gln Gly
Ala Asn Ala Met
Ala Asn Cys Val
Ala Asn Asp Ser
Ala Asn Met Ala
Ala Asn Ser Asp
Ala Asn Thr Thr
C15H27N5O8 (405.18595419999997)
Ala Asn Val Cys
Ala Gln Gly Met
Ala Gln Met Gly
Ala Gln Ser Thr
C15H27N5O8 (405.18595419999997)
Ala Gln Thr Ser
C15H27N5O8 (405.18595419999997)
Ala Arg Cys Gly
Ala Arg Gly Cys
Ala Ser Asp Asn
Ala Ser Asn Asp
Ala Ser Gln Thr
C15H27N5O8 (405.18595419999997)
Ala Ser Thr Gln
C15H27N5O8 (405.18595419999997)
Ala Thr Asn Thr
C15H27N5O8 (405.18595419999997)
Ala Thr Gln Ser
C15H27N5O8 (405.18595419999997)
Ala Thr Ser Gln
C15H27N5O8 (405.18595419999997)
Ala Thr Thr Asn
C15H27N5O8 (405.18595419999997)
Ala Val Cys Asn
Ala Val Asn Cys
Cys Ala Gly Arg
Cys Ala Asn Val
Cys Ala Arg Gly
Cys Ala Val Asn
Cys Gly Ala Arg
Cys Gly Ile Asn
Cys Gly Leu Asn
Cys Gly Asn Ile
Cys Gly Asn Leu
Cys Gly Gln Val
Cys Gly Arg Ala
Cys Gly Val Gln
Cys Ile Gly Asn
Cys Ile Asn Gly
Cys Leu Gly Asn
Cys Leu Asn Gly
Cys Asn Ala Val
Cys Asn Gly Ile
Cys Asn Gly Leu
Cys Asn Ile Gly
Cys Asn Leu Gly
Cys Asn Val Ala
Cys Gln Gly Val
Cys Gln Val Gly
Cys Arg Ala Gly
Cys Arg Gly Ala
Cys Val Ala Asn
Cys Val Gly Gln
Cys Val Asn Ala
Cys Val Gln Gly
Asp Ala Asn Ser
Asp Ala Ser Asn
Asp Gly Asn Thr
Asp Gly Gln Ser
Asp Gly Ser Gln
Asp Gly Thr Asn
Asp Asn Ala Ser
Asp Asn Gly Thr
Asp Asn Ser Ala
Asp Asn Thr Gly
Asp Gln Gly Ser
Asp Gln Ser Gly
Asp Ser Ala Asn
Asp Ser Gly Gln
Asp Ser Asn Ala
Asp Ser Gln Gly
Asp Thr Gly Asn
Asp Thr Asn Gly
Glu Gly Asn Ser
Glu Gly Ser Asn
Glu Asn Gly Ser
Glu Asn Ser Gly
Glu Ser Gly Asn
Glu Ser Asn Gly
Gly Ala Cys Arg
Gly Ala Met Gln
Gly Ala Gln Met
Gly Ala Arg Cys
Gly Cys Ala Arg
Gly Cys Ile Asn
Gly Cys Leu Asn
Gly Cys Asn Ile
Gly Cys Asn Leu
Gly Cys Gln Val
Gly Cys Arg Ala
Gly Cys Val Gln
Gly Asp Asn Thr
Gly Asp Gln Ser
Gly Asp Ser Gln
Gly Asp Thr Asn
Gly Glu Asn Ser
Gly Glu Ser Asn
Gly Gly Ser Trp
Gly Gly Trp Ser
Gly Ile Cys Asn
Gly Ile Asn Cys
Gly Leu Cys Asn
Gly Leu Asn Cys
Gly Met Ala Gln
Gly Met Gln Ala
Gly Asn Cys Ile
Gly Asn Cys Leu
Gly Asn Asp Thr
Gly Asn Glu Ser
Gly Asn Ile Cys
Gly Asn Leu Cys
Gly Asn Ser Glu
Gly Asn Thr Asp
Gly Gln Ala Met
Gly Gln Cys Val
Gly Gln Asp Ser
Gly Gln Met Ala
Gly Gln Ser Asp
Gly Gln Val Cys
Gly Arg Ala Cys
Gly Arg Cys Ala
Gly Ser Asp Gln
Gly Ser Glu Asn
Gly Ser Gly Trp
Gly Ser Asn Glu
Gly Ser Gln Asp
Gly Ser Trp Gly
Gly Thr Asp Asn
Gly Thr Asn Asp
Gly Val Cys Gln
Gly Val Gln Cys
Gly Trp Gly Ser
Gly Trp Ser Gly
Ile Cys Gly Asn
Ile Cys Asn Gly
Ile Gly Cys Asn
Ile Gly Asn Cys
Ile Asn Cys Gly
Ile Asn Gly Cys
Leu Cys Gly Asn
Leu Cys Asn Gly
Leu Gly Cys Asn
Leu Gly Asn Cys
Leu Asn Cys Gly
Leu Asn Gly Cys
Met Ala Ala Asn
Met Ala Gly Gln
Met Ala Asn Ala
Met Ala Gln Gly
Met Gly Ala Gln
Met Gly Gln Ala
Met Asn Ala Ala
Met Gln Ala Gly
Met Gln Gly Ala
Asn Ala Ala Met
Asn Ala Cys Val
Asn Ala Asp Ser
Asn Ala Met Ala
Asn Ala Ser Asp
Asn Ala Val Cys
Asn Cys Ala Val
Asn Cys Gly Ile
Asn Cys Gly Leu
Asn Cys Ile Gly
Asn Cys Leu Gly
Asn Cys Val Ala
Asn Asp Ala Ser
Asn Asp Gly Thr
Asn Asp Ser Ala
Asn Asp Thr Gly
Asn Glu Gly Ser
Asn Glu Ser Gly
Asn Gly Cys Ile
Asn Gly Cys Leu
Asn Gly Asp Thr
Asn Gly Glu Ser
Asn Gly Ile Cys
Asn Gly Leu Cys
Asn Gly Ser Glu
Asn Gly Thr Asp
Asn Ile Cys Gly
Asn Ile Gly Cys
Asn Leu Cys Gly
Asn Leu Gly Cys
Asn Met Ala Ala
Asn Ser Ala Asp
Asn Ser Asp Ala
Asn Ser Glu Gly
Asn Ser Gly Glu
Asn Thr Asp Gly
Asn Thr Gly Asp
Asn Val Ala Cys
Asn Val Cys Ala
Gln Ala Gly Met
Gln Ala Met Gly
Gln Cys Gly Val
Gln Cys Val Gly
Gln Asp Gly Ser
Gln Asp Ser Gly
Gln Gly Ala Met
Gln Gly Cys Val
Gln Gly Asp Ser
Gln Gly Met Ala
Gln Gly Ser Asp
Gln Gly Val Cys
Gln Met Ala Gly
Gln Met Gly Ala
Gln Ser Asp Gly
Gln Ser Gly Asp
Gln Val Cys Gly
Gln Val Gly Cys
Arg Ala Cys Gly
Arg Ala Gly Cys
Arg Cys Ala Gly
Arg Cys Gly Ala
Arg Gly Ala Cys
Arg Gly Cys Ala
Ser Ala Asp Asn
Ser Asp Ala Asn
Ser Asp Gly Gln
Ser Asp Asn Ala
Ser Asp Gln Gly
Ser Glu Gly Asn
Ser Glu Asn Gly
Ser Gly Asp Gln
Ser Gly Glu Asn
Ser Gly Gly Trp
Ser Gly Asn Glu
Ser Gly Gln Asp
Ser Gly Trp Gly
Ser Asn Ala Asp
Ser Asn Asp Ala
Ser Asn Glu Gly
Ser Asn Gly Glu
Ser Gln Asp Gly
Ser Gln Gly Asp
Ser Trp Gly Gly
Thr Asp Gly Asn
Thr Asp Asn Gly
Thr Gly Asp Asn
Thr Gly Asn Asp
Thr Asn Asp Gly
Thr Asn Gly Asp
Val Ala Cys Asn
Val Ala Asn Cys
Val Cys Ala Asn
Val Cys Gly Gln
Val Cys Asn Ala
Val Cys Gln Gly
Val Gly Cys Gln
Val Gly Gln Cys
Val Asn Ala Cys
Val Asn Cys Ala
Val Gln Cys Gly
Val Gln Gly Cys
Trp Gly Gly Ser
Trp Gly Ser Gly
Trp Ser Gly Gly
Nebivolol
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4-Hydroxyphenylacetonitrile triacetylrhamnoside
Epolactaene
C21H27NO7 (405.17874320000004)
Tetranor PGE1 Taurine
C18H31NO7S (405.18211360000004)
icas#12
C21H27NO7 (405.17874320000004)
A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (5R)-5-hydroxyhexanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.
SEROTONIN CREATININE SULFATE MONOHYDRATE
C14H23N5O7S (405.13181280000003)
5-Hydroxytryptamine creatinine sulfate monohydrate is an endogenous metabolite.
[3-(1,3-benzoxazol-2-yl)-2-oxochromen-7-yl] octanoate
C24H23NO5 (405.15761480000003)
Heroin hydrochloride
C21H24ClNO5 (405.13429240000005)
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
(S)-2-((TERT-BUTOXYCARBONYL)AMINO)-3-PHENYLPROPYL 4-METHYLBENZENESULFONATE
C21H27NO5S (405.1609852000001)
fmoc-(s)-3-amino-3-(2-fluoro-phenyl)-propionic acid
C24H20FNO4 (405.13762920000005)
fmoc-(r)-3-amino-3-(3-fluoro-phenyl)-propionic acid
C24H20FNO4 (405.13762920000005)
1-(2,2-Dimethoxyethyl)-1,4-dihydro-4-oxo-3-(phenylmethoxy)-2,5-pyridinedicarboxylic acid 2,5-dimethyl ester
fmoc-(r)-3-amino-3-(2-fluoro-phenyl)-propionic acid
C24H20FNO4 (405.13762920000005)
N-[4-(2-Methyl-2-propanyl)benzyl]-N-{3-[(methylsulfonyl)amino]be nzyl}carbamimidothioic acid
2-[[(4-Chlorophenyl) methylhydrazono]methyl]-1-(2-methoxyethyl)-3,3-dimethyl-3H-indolium chloride
morclofone
C21H24ClNO5 (405.13429240000005)
R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent
2,7-Dichloro-Alpha-[(Dibutylamino)Methyl]-9H-Fluorene-4-Methanol
SGI-1776 free base
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Adoprazine
Adoprazine (SLV313) is a full 5-HT1A receptor agonist with a pEC50 of 9 at cloned h5-HT1A receptors. Adoprazine (SLV313) is a full D2 and D3 receptor antagonist with pA2s of 9.3 and 8.9 at hD2 and hD3 receptors, respectively. Adoprazine (SLV313) has the characteristics of atypical antipsychotics[1].
3-(6-chloro-1-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane
C19H24ClN5O3 (405.15675840000006)
2-Chloro-N-[(1-hydroxycycloheptyl)methyl]-5-[1-(2-hydroxyethyl)-5 -methyl-1H-pyrazol-3-yl]benzamide
C21H28ClN3O3 (405.1819088000001)
p-Amidinophenyl p-(6-amidino-2-indolyl)phenyl ether dihydrochloride
C22H20ClN5O (405.13563000000005)
TERT-BUTYL (2S,3S)-1-(4-(BENZYLOXY)PHENYL)-4-CHLORO-3-HYDROXYBUTAN-2-YLCARBAMATE
C22H28ClNO4 (405.1706758000001)
(R)-2-(3-(DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4-METHYLPHENOL HYDROBROMIDE
Taltirelin
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C76367 - Thyrotropin-Releasing Hormone Analogue D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D002491 - Central Nervous System Agents > D018697 - Nootropic Agents
fmoc-(r)-3-amino-3-(4-fluoro-phenyl)-propionic acid
C24H20FNO4 (405.13762920000005)
Spiro[9H-fluorene-9,8-[8H]indolo[3,2,1-de]acridine]
Spiro[9H-fluorene-9,7(12H)-indeno[1,2-a]carbazole]
3-n-fmoc-3-(4-fluorophenyl)propionic acid
C24H20FNO4 (405.13762920000005)
N-[2-[(2,6-dicyano-4-nitrophenyl)azo]-5-(diethylamino)phenyl]acetamide
3-(2-aminoethyl)-1H-indol-6-ol,2-amino-3-methyl-4H-imidazol-5-one,sulfuric acid
C14H23N5O7S (405.13181280000003)
fmoc-(s)-3-amino-3-(3-fluoro-phenyl)-propionic acid
C24H20FNO4 (405.13762920000005)
(S)-3-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)AMINO)-3-(4-FLUOROPHENYL)PROPANOIC ACID
C24H20FNO4 (405.13762920000005)
Mazaticol
N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent
4-[(5-{[4-(3-Chlorophenyl)-3-oxopiperazin-1-YL]methyl}-1H-imidazol-1-YL)methyl]benzonitrile
C22H20ClN5O (405.13563000000005)
Oxycodone hydrochloride trihydrate
C18H28ClNO7 (405.15542080000006)
N-Des[2-(1-methyl-2-pyrrolidinyl)ethyl] Udenafil
C18H23N5O4S (405.14706780000006)
(5R)-5-[[3,6-Dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy]hexanoic acid
C21H27NO7 (405.17874320000004)
2-[(5-Phenyl-1,3,4-oxadiazol-2-yl)thio]-1-(2,2,4,6-tetramethyl-1-quinolinyl)ethanone
Methyl 5-[[2-[(3-methylphenyl)methyl]-1-oxo-3,4-dihydroisoquinolin-5-yl]oxymethyl]furan-2-carboxylate
C24H23NO5 (405.15761480000003)
2-{3-[(2s)-4,4-Difluoro-2-(Pyrrolidin-1-Ylcarbonyl)pyrrolidin-1-Yl]-3-Oxopropyl}-Isoindole-1,3(2h)-Dione
9-Butyl-8-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
C19H24ClN5O3 (405.15675840000006)
Clomifene
C26H28ClNO (405.18593080000005)
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03G - Gonadotropins and other ovulation stimulants > G03GB - Ovulation stimulants, synthetic D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen D012102 - Reproductive Control Agents > D005299 - Fertility Agents C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor
N-acetylphosphinothricyl-L-alanyl-L-leucine
C16H28N3O7P-2 (405.16647880000005)
7-hydroxy-8-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-2,2-dimethyl-6-(3-methylbut-2-enyl)chromen-5-olate
(2S,3S,6R)-3-[[2-(2-amino-3-methyl-1,4,5,6-tetrahydropyrimidin-3-ium-6-yl)acetyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylate
7,8-dimethyl-4-oxo-10-[(2S,3R,4S,5R)-2,3,4,5,6-pentahydroxyhexyl]benzo[g]pteridin-2-olate
2-(4-(4-Chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine
C26H28ClNO (405.18593080000005)
11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1-nitro-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
C21H27NO7 (405.17874320000004)
1-(2-Chloro-4-methylphenyl)-3-[[1-[(3-chlorophenyl)methyl]-4-piperidinyl]methyl]urea
1-(4-Chlorophenyl)-5-[1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinyl]-4-pyrazolecarboxylic acid
C20H24ClN3O4 (405.14552540000005)
1-[1-[4-[(4-chlorophenyl)methoxy]phenyl]-2,5-dimethylpyrrol-3-yl]-N-(1,2,4-triazol-4-yl)methanimine
C22H20ClN5O (405.13563000000005)
Diethyl 3-methyl-5-[[2-(pyridin-2-ylmethylamino)acetyl]amino]thiophene-2,4-dicarboxylate
C19H23N3O5S (405.13583480000005)
N-[2-(4-methoxyphenyl)ethyl]-2-nitro-4-(1-pyrrolidinylsulfonyl)aniline
C19H23N3O5S (405.13583480000005)
5-(4-ethylsulfonyl-1-piperazinyl)-2-nitro-N-(3-pyridinylmethyl)aniline
C18H23N5O4S (405.14706780000006)
3-[[5,6-Bis(4-methoxyphenyl)-4-furo[2,3-d]pyrimidinyl]amino]-1-propanol
C23H23N3O4 (405.16884780000004)
2-(2-Furanylmethylamino)benzoic acid [2-oxo-2-(3-oxo-2,4-dihydroquinoxalin-1-yl)ethyl] ester
C22H19N3O5 (405.13246440000006)
5-amino-N-(2-methoxy-5-methylphenyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-4-triazolecarboxamide
N-[2,5-diethoxy-4-[[(2-methylpropylamino)-sulfanylidenemethyl]amino]phenyl]-2-furancarboxamide
C20H27N3O4S (405.1722182000001)
2-(Butylamino)benzoic acid [2-oxo-2-(4-sulfamoylanilino)ethyl] ester
C19H23N3O5S (405.13583480000005)
4-pyrazol-1-yl-N,N-bis(pyridin-2-ylmethyl)benzenesulonamide
C21H19N5O2S (405.12593940000005)
4-[(1-methyl-2-oxo-4-quinolinyl)oxy]-N-[4-(trifluoromethyl)-2-pyridinyl]butanamide
C20H18F3N3O3 (405.13001940000004)
(2S,3S,6R)-3-[[2-(2-amino-1-methyl-5,6-dihydro-4H-pyrimidin-4-yl)acetyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylic acid
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
C21H27NO7 (405.17874320000004)
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
C21H27NO7 (405.17874320000004)
(2S)-2-[(4R,5S)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
C20H27N3O4S (405.1722182000001)
(2S)-2-[(4R,5R)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
C20H27N3O4S (405.1722182000001)
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
C21H27NO7 (405.17874320000004)
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
C21H27NO7 (405.17874320000004)
(1S,5R)-6-(2-methylphenyl)sulfonyl-7-[4-(3-pyridinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane
[(2S,3R)-2-(hydroxymethyl)-3-phenyl-6-(2-thiazolylmethyl)-1,6-diazaspiro[3.3]heptan-1-yl]-phenylmethanone
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C23H23N3O4 (405.16884780000004)
(6R,7S,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C23H23N3O4 (405.16884780000004)
(6S,7R,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C23H23N3O4 (405.16884780000004)
(2R)-2-[(4S,5S)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
C20H27N3O4S (405.1722182000001)
(2R)-2-[(4R,5R)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
C20H27N3O4S (405.1722182000001)
(2S)-2-[(4S,5S)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
C20H27N3O4S (405.1722182000001)
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
C21H27NO7 (405.17874320000004)
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
C21H27NO7 (405.17874320000004)
[(2S,3S)-2-(hydroxymethyl)-3-phenyl-6-(2-thiazolylmethyl)-1,6-diazaspiro[3.3]heptan-1-yl]-phenylmethanone
[(2R,3R)-2-(hydroxymethyl)-3-phenyl-6-(2-thiazolylmethyl)-1,6-diazaspiro[3.3]heptan-1-yl]-phenylmethanone
(6S,7S,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C23H23N3O4 (405.16884780000004)
(6R,7S,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C23H23N3O4 (405.16884780000004)
(6R,7R,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C23H23N3O4 (405.16884780000004)
(6S,7S,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C23H23N3O4 (405.16884780000004)
(6S,7R,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
C23H23N3O4 (405.16884780000004)
[4,5-Diacetyloxy-6-[4-(cyanomethyl)phenoxy]-2-methyloxan-3-yl] acetate
(2E,5Z)-5-{[1-(2,4-difluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]methylidene}-2-[(2-methoxyethyl)imino]-3-methyl-1,3-thiazolidin-4-one
Adenosine, N-(2-hydroxycyclopentyl)-, (1S-trans)-[CAS]
2-(3-Trimethylsilyloxybutoxy)-4-quinolinecarboxylic acid trimethylsilyl ester
C20H31NO4Si2 (405.17915260000007)
Glu-Glu-Glu
A tripeptide composed of three L-glutamic acid units joined by peptide linkages.
JZP-361
C22H20ClN5O (405.13563000000005)
JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC50 of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research[1]. JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC50 of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research[1].
1-{17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-yl}propan-2-one
C24H23NO5 (405.15761480000003)
1-[(20r)-16,17-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14(19),15,17-octaen-20-yl]propan-2-one
C24H23NO5 (405.15761480000003)
1-{15,16-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-11-yl}propan-2-one
C24H23NO5 (405.15761480000003)
(2s,3r,4r,5s,6s)-4,5-bis(acetyloxy)-2-[4-(cyanomethyl)phenoxy]-6-methyloxan-3-yl acetate
8-(dimethylamino)-4-hydroxy-7-methyl-10-(2,3,4,5-tetrahydroxypentyl)benzo[g]pteridin-2-one
1-{17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-11-yl}propan-2-one
C24H23NO5 (405.15761480000003)